25,704 AbbVie Inc. $ABBV Shares Bought by Vise Technologies Inc.

01 Nov 2026, 12:48 by Danessa Lincoln · The Markets Daily

Vise Technologies Inc. increased its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 21.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 143,948 shares of the company’s stock after acquiring an additional 25,704 shares during the period. Vise Technologies Inc.’s holdings in AbbVie were worth $37,655,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Investment Partners LTD. increased its holdings in shares of AbbVie by 82.2% in the third quarter. Investment Partners LTD. now owns 10,925 shares of the company’s stock valued at $2,858,000 after purchasing an additional 4,928 shares during the period. Global Assets Advisory LLC grew its holdings in shares of AbbVie by 1.7% during the third quarter. Global Assets Advisory LLC now owns 7,625 shares of the company’s stock valued at $2,008,000 after purchasing an additional 126 shares during the last quarter. Summit Global Investments raised its stake in shares of AbbVie by 45.1% in the 3rd quarter. Summit Global Investments now owns 16,792 shares of the company’s stock worth $4,393,000 after buying an additional 5,220 shares in the last quarter. Coyle Financial Counsel LLC boosted its position in shares of AbbVie by 3.1% in the third quarter. Coyle Financial Counsel LLC now owns 8,020 shares of the company’s stock worth $2,098,000 after buying an additional 240 shares during the period. Finally, Sagace Wealth Management LLC acquired a new stake in shares of AbbVie during the 3rd quarter valued at about $235,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ABBV. Leerink Partners lifted their price target on shares of AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Canaccord Genuity Group increased their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. UBS Group boosted their price target on AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a research note on Tuesday, October 6th. Weiss Ratings upgraded shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Finally, Morgan Stanley increased their price objective on AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $279.86.

Get Our Latest Research Report on AbbVie

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

AbbVie Trading Up 1.4%

Shares of AbbVie stock opened at $294.80 on Friday. The firm has a market capitalization of $520.85 billion, a PE ratio of 50.74, a P/E/G ratio of 1.35 and a beta of 0.24. The firm’s 50-day moving average price is $269.35 and its 200 day moving average price is $237.23. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $298.74.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter in the previous year, the business earned $1.86 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, sell-side analysts predict that AbbVie Inc. will post 13.92 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is 195.48%.

AbbVie Company Profile

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.